OBJECTIVES: Cytochrome P450 enzymes play a dominant role in drug elimination and variation in these genes is a major source of interindividual differences in drug response. Little is known, however, about pharmacogenetic variation in American Indian and Alaska Native (AI/AN) populations. We have developed a partnership with the Confederated Salish and Kootenai Tribes (CSKT) in northwestern Montana to address this knowledge gap. METHODS: We resequenced CYP2D6 in 187 CSKT individuals and CYP3A4, CYP3A5, and CYP2C9 in 94 CSKT individuals. RESULTS: We identified 67 variants in CYP2D6, 15 in CYP3A4, 10 in CYP3A5, and 41 in CYP2C9. The most common CYP2D6 alleles were CYP2D6*4 and *41 (20.86 and 11.23%, respectively). CYP2D6*3, *5, *6, *9, *10, *17, *28, *33, *35, *49, *1xN, *2xN, and *4xN frequencies were less than 2%. CYP3A5*3, CYP3A4*1G, and *1B were detected with frequencies of 92.47, 26.81, and 2.20%, respectively. Allelic variation in CYP2C9 was low: CYP2C9*2 (5.17%) and *3 (2.69%). In general, allele frequencies in CYP2D6, CYP2C9, and CYP3A5 were similar to those observed in European Americans. There was, however, a marked divergence in CYP3A4 for the CYP3A4*1G allele. We also observed low levels of linkage between CYP3A4*1G and CYP3A5*1 in the CSKT. The combination of nonfunctional CYP3A5*3 and putative reduced function CYP3A4*1G alleles may predict diminished clearance of CYP3A substrates. CONCLUSION: These results highlight the importance of carrying out pharmacogenomic research in AI/AN populations and show that extrapolation from other populations is not appropriate. This information could help optimize drug therapy for the CSKT population.
OBJECTIVES:Cytochrome P450 enzymes play a dominant role in drug elimination and variation in these genes is a major source of interindividual differences in drug response. Little is known, however, about pharmacogenetic variation in American Indian and Alaska Native (AI/AN) populations. We have developed a partnership with the Confederated Salish and Kootenai Tribes (CSKT) in northwestern Montana to address this knowledge gap. METHODS: We resequenced CYP2D6 in 187 CSKT individuals and CYP3A4, CYP3A5, and CYP2C9 in 94 CSKT individuals. RESULTS: We identified 67 variants in CYP2D6, 15 in CYP3A4, 10 in CYP3A5, and 41 in CYP2C9. The most common CYP2D6 alleles were CYP2D6*4 and *41 (20.86 and 11.23%, respectively). CYP2D6*3, *5, *6, *9, *10, *17, *28, *33, *35, *49, *1xN, *2xN, and *4xN frequencies were less than 2%. CYP3A5*3, CYP3A4*1G, and *1B were detected with frequencies of 92.47, 26.81, and 2.20%, respectively. Allelic variation in CYP2C9 was low: CYP2C9*2 (5.17%) and *3 (2.69%). In general, allele frequencies in CYP2D6, CYP2C9, and CYP3A5 were similar to those observed in European Americans. There was, however, a marked divergence in CYP3A4 for the CYP3A4*1G allele. We also observed low levels of linkage between CYP3A4*1G and CYP3A5*1 in the CSKT. The combination of nonfunctional CYP3A5*3 and putative reduced function CYP3A4*1G alleles may predict diminished clearance of CYP3A substrates. CONCLUSION: These results highlight the importance of carrying out pharmacogenomic research in AI/AN populations and show that extrapolation from other populations is not appropriate. This information could help optimize drug therapy for the CSKT population.
Authors: Silvana Borges; Zeruesenay Desta; Lang Li; Todd C Skaar; Bryan A Ward; Anne Nguyen; Yan Jin; Anna Maria Storniolo; D Michele Nikoloff; Lin Wu; Grant Hillman; Daniel F Hayes; Vered Stearns; David A Flockhart Journal: Clin Pharmacol Ther Date: 2006-07 Impact factor: 6.875
Authors: Cristina Rodríguez-Antona; Jane G Sayi; Lars L Gustafsson; Leif Bertilsson; Magnus Ingelman-Sundberg Journal: Biochem Biophys Res Commun Date: 2005-09-13 Impact factor: 3.575
Authors: E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski Journal: Pharmacogenetics Date: 2001-12
Authors: Yvonne S Lin; Amy L S Dowling; Sean D Quigley; Federico M Farin; Jiong Zhang; Jatinder Lamba; Erin G Schuetz; Kenneth E Thummel Journal: Mol Pharmacol Date: 2002-07 Impact factor: 4.436
Authors: M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena Journal: Pharmacogenomics J Date: 2016-06-07 Impact factor: 3.550
Authors: Alison E Fohner; Renee Robinson; Joseph Yracheta; Denise A Dillard; Brian Schilling; Burhan Khan; Scarlett Hopkins; Bert Boyer; Jynene Black; Howard Wiener; Hemant K Tiwari; Adam Gordon; Deborah Nickerson; Jesse M Tsai; Federico M Farin; Timothy A Thornton; Allan E Rettie; Kenneth E Thummel Journal: Pharmacogenet Genomics Date: 2015-07 Impact factor: 2.089
Authors: Jaedon P Avey; Vanessa Y Hiratsuka; Julie A Beans; Susan Brown Trinidad; Rachel F Tyndale; Renee F Robinson Journal: Pharmacogenomics Date: 2016-02-12 Impact factor: 2.533
Authors: Julie A Beans; Vanessa Y Hiratsuka; Charlene R Apok; Karen Caindec; Denise A Dillard; Renee F Robinson Journal: Am Indian Alsk Native Ment Health Res Date: 2018
Authors: Moataz E Mohamed; David P Schladt; Weihua Guan; Baolin Wu; Jessica van Setten; Brendan J Keating; David Iklé; Rory P Remmel; Casey R Dorr; Roslyn B Mannon; Arthur J Matas; Ajay K Israni; William S Oetting; Pamala A Jacobson Journal: Am J Transplant Date: 2019-05-13 Impact factor: 8.086
Authors: Elizabeth H Dorfman; Susan Brown Trinidad; Chelsea T Morales; Kevin Howlett; Wylie Burke; Erica L Woodahl Journal: Pharmacogenomics Date: 2015 Impact factor: 2.533
Authors: Chelsea T Morales; LeeAnna I Muzquiz; Kevin Howlett; Bernie Azure; Brenda Bodnar; Vernon Finley; Tony Incashola; Cheryl Mathias; Cindi Laukes; Patrick Beatty; Wylie Burke; Mark A Pershouse; Elizabeth A Putnam; Susan Brown Trinidad; Rosalina James; Erica L Woodahl Journal: Prog Community Health Partnersh Date: 2016